,trial,lopinavirritonavir,adults,hospitalized,severe,covid19
background,therapeutics,have,yet,been,proven,effective,treatment,severe,illness,caused,sarscov2
methods,conducted,randomized,controlled,openlabel,trial,involving,hospitalized,adult,patients,confirmed,sarscov2,infection,causes,respiratory,illness,covid19,oxygen,saturation,sao2,94,less,breathing,ambient,air,ratio,partial,pressure,oxygen,pao2,fraction,inspired,oxygen,fio2,less,300,hg
patients,randomly,assigned,11,ratio,receive,lopinavirritonavir,400,100,respectively,twice,day,14,days,addition,standard,care,standard,care,alone
,primary,end,point,was,time,clinical,improvement,defined,time,randomization,improvement,two,points,sevencategory,ordinal,scale,discharge,hospital,whichever,came,first
results,total,199,patients,laboratoryconfirmed,sarscov2,infection,underwent,randomization,99,assigned,lopinavirritonavir,group,100,standardcare,group
treatment,lopinavirritonavir,was,not,associated,difference,standard,care,time,clinical,improvement,hazard,ratio,clinical,improvement,124,95,confidence,interval,ci,090,172
mortality,28,days,was,similar,lopinavirritonavir,group,standardcare,group,192,vs,250
,percentages,patients,detectable,viral,rna,time,points,similar
,modified,intentiontreat,analysis,lopinavirritonavir,led,median,time,clinical,improvement,was,shorter,1,day,observed,standard,care,hazard,ratio,139,95,ci,100,191
gastrointestinal,adverse,events,more,common,lopinavirritonavir,group,serious,adverse,events,more,common,standardcare,group
lopinavirritonavir,treatment,was,stopped,early,13,patients,138,adverse,events
,hospitalized,adult,patients,severe,covid19,benefit,was,observed,lopinavirritonavir,treatment,beyond,standard,care
future,trials,patients,severe,illness,help,confirm,exclude,possibility,treatment,benefit
funded,major,projects,national,science,technology,new,drug,creation,development,others,chinese,clinical,trial,register,number,chictr2000029308
remdesivir,adults,severe,covid19,randomised,doubleblind,placebocontrolled,multicentre,trial
background,specific,antiviral,drug,has,been,proven,effective,treatment,patients,severe,coronavirus,disease,2019,covid19
remdesivir,gs5734,nucleoside,analogue,prodrug,has,inhibitory,effects,pathogenic,animal,human,coronaviruses,including,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,vitro,inhibits,middle,east,respiratory,syndrome,coronavirus,sarscov1,sarscov2,replication,animal,models
methods,did,randomised,doubleblind,placebocontrolled,multicentre,trial,ten,hospitals,hubei,china
eligible,patients,adults,aged,18,years,admitted,hospital,laboratoryconfirmed,sarscov2,infection,interval,symptom,onset,enrolment,12,days,less,oxygen,saturation,94,less,room,air,ratio,arterial,oxygen,partial,pressure,fractional,inspired,oxygen,300,hg,less,radiologically,confirmed,pneumonia
patients,randomly,assigned,21,ratio,intravenous,remdesivir,200,day,1,followed,100,days,210,single,daily,infusions,same,volume,placebo,infusions,10,days
patients,permitted,concomitant,use,lopinavirritonavir,interferons,corticosteroids
,primary,endpoint,was,time,clinical,improvement,up,day,28,defined,time,days,randomisation,point,decline,two,levels,sixpoint,ordinal,scale,clinical,status,1discharged,6death,discharged,alive,hospital,whichever,came,first
primary,analysis,was,intentiontreat,itt,population,safety,analysis,was,patients,who,started,assigned,treatment
,trial,is,registered,clinicaltrialsgov
findings,feb,6,2020,march,12,2020,237,patients,enrolled,randomly,assigned,treatment,group,158,remdesivir,79,placebo,one,patient,placebo,group,who,withdrew,after,randomisation,was,not,included,itt,population
remdesivir,use,was,not,associated,difference,time,clinical,improvement,hazard,ratio,1,23,95,ci,0,871,75
,not,statistically,significant,patients,receiving,remdesivir,had,numerically,faster,time,clinical,improvement,receiving,placebo,patients,symptom,duration,10,days,less,hazard,ratio,1,52,0,952,43
adverse,events,reported,102,66,155,remdesivir,recipients,versus,50,64,78,placebo,recipients
remdesivir,was,stopped,early,adverse,events,18,12,patients,versus,four,5,patients,who,stopped,placebo,early
interpretation,study,adult,patients,admitted,hospital,severe,covid19,remdesivir,was,not,associated,statistically,significant,clinical,benefits
,numerical,reduction,time,clinical,improvement,treated,earlier,requires,confirmation,larger,studies
funding,chinese,academy,medical,sciences,emergency,project,covid19,national,key,research,development,program,china,beijing,science,technology,project
respiratory,rehabilitation,elderly,patients,covid19,randomized,controlled,study
background,different,degrees,disorders,reported,respiratory,function,physical,function,psychological,function,patients,corona,virus,disease,2019,covid19,elderly,patients
,experience,improved,discharged,covid19,patients,timely,respiratory,rehabilitation,intervention,improve,prognosis,maximize,functional,preservation,improve,quality,life,qol,lacks,studies,worldwide,exploring,outcome,intervention
objective,investigate,effects,6week,respiratory,rehabilitation,training,respiratory,function,qol,mobility,psychological,function,elderly,patients,covid19
methods,paper,reported,findings,observational,prospective,quasiexperimental,study,totally,recruited,72,participants,36,patients,underwent,respiratory,rehabilitation,rest,rehabilitation,intervention
,following,outcomes,measured,pulmonary,function,tests,including,plethysmography,diffusing,lung,capacity,carbon,monoxide,dlco,functional,tests,6min,walk,distance,test,quality,life,qol,assessments,sf36,scores,activities,daily,living,functional,independence,measure,fim,scores,mental,status,tests,sas,anxiety,sds,depression,scores
results,after,6,weeks,respiratory,rehabilitation,intervention,group,disclosed,significant,differences,fev1l,fvcl,fev1fvc,dlco,6min,walk,test
,sf36,scores,8,dimensions,statistically,significant,intervention,group,two,groups
sas,sds,scores,intervention,group,decreased,after,intervention,only,anxiety,had,significant,statistical,significance,two,groups
,sixweek,respiratory,rehabilitation,improve,respiratory,function,qol,anxiety,elderly,patients,covid19,has,little,significant,improvement,depression,elderly
patients,cancer,appear,more,vulnerable,sarscov2,multicenter,study,covid19,outbreak
,novel,covid19,outbreak,has,affected,more,200,countries,territories,march,2020
given,patients,cancer,generally,more,vulnerable,infections,systematic,analysis,diverse,cohorts,patients,cancer,affected,covid19,needed
,performed,multicenter,study,including,105,cancer,patients,536,agematched,noncancer,patients,confirmed,covid19
,results,covid19,patients,cancer,had,higher,risks,severe,outcomes
patients,hematological,cancer,lung,cancer,metastatic,cancer,stage,iv,had,highest,frequency,severe,events
nonmetastatic,cancer,patients,experienced,similar,frequencies,severe,conditions,observed,patients,cancer
patients,who,received,surgery,had,higher,risks,having,severe,events,patients,only,radiotherapy,did,not,demonstrate,significant,differences,severe,events,compared,patients,cancer
,findings,indicate,cancer,patients,appear,more,vulnerable,sarscov2,outbreak
safety,tolerability,immunogenicity,recombinant,adenovirus,type5,vectored,covid19,vaccine,doseescalation,openlabel,nonrandomised,firsthuman,trial
background,vaccine,protect,against,covid19,is,urgently,needed
,aimed,assess,safety,tolerability,immunogenicity,recombinant,adenovirus,type5,ad5,vectored,covid19,vaccine,expressing,spike,glycoprotein,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,strain
methods,did,doseescalation,singlecentre,openlabel,nonrandomised,phase,1,trial,ad5,vectored,covid19,vaccine,wuhan,china
healthy,adults,aged,18,60,years,sequentially,enrolled,allocated,one,three,dose,groups,5,x,1010,1,x,1011,1,5,x,1011,viral,particles,receive,intramuscular,injection,vaccine
,primary,outcome,was,adverse,events,7,days,postvaccination
safety,was,assessed,over,28,days,postvaccination
specific,antibodies,measured,elisa,neutralising,antibody,responses,induced,vaccination,detected,sarscov2,virus,neutralisation,pseudovirus,neutralisation,tests
tcell,responses,assessed,enzymelinked,immunospot,flowcytometry,assays
,study,is,registered,clinicaltrialsgov
findings,march,16,march,27,2020,screened,195,individuals,eligibility
,108,participants,51,male,49,female,mean,age,36,3,years,recruited,received,low,dose,n36,middle,dose,n36,high,dose,n36,vaccine
,enrolled,participants,included,analysis
,least,one,adverse,reaction,first,7,days,after,vaccination,was,reported,30,83,participants,low,dose,group,30,83,participants,middle,dose,group,27,75,participants,high,dose,group
,common,injection,site,adverse,reaction,was,pain,was,reported,58,54,vaccine,recipients,commonly,reported,systematic,adverse,reactions,fever,50,46,fatigue,47,44,headache,42,39,muscle,pain,18,17
,adverse,reactions,reported,dose,groups,mild,moderate,severity
,serious,adverse,event,was,noted,28,days,postvaccination
elisa,antibodies,neutralising,antibodies,increased,day,14,peaked,28,days,postvaccination
specific,tcell,response,peaked,day,14,postvaccination
interpretation,ad5,vectored,covid19,vaccine,is,tolerable,immunogenic,28,days,postvaccination
humoral,responses,against,sarscov2,peaked,day,28,postvaccination,healthy,adults,rapid,specific,tcell,responses,noted,day,14,postvaccination
,findings,suggest,ad5,vectored,covid19,vaccine,warrants,investigation
funding,national,key,rd,program,china,national,science,technology,major,project,cansino,biologics
,pilot,study,hydroxychloroquine,treatment,patients,moderate,covid19
objective,evaluate,efficacy,safety,hydroxychloroquine,hcq,treatment,patients,moderate,coronavirus,disease,2019,covid19
methods,prospectively,enrolled,30,treatmentnaive,patients,confirmed,covid19,after,informed,consent,shanghai,public,health,clinical,center
,patients,randomized,11,hcq,group,control,group
patients,hcq,group,given,hcq,400,per,day,5,days,plus,conventional,treatments,control,group,given,conventional,treatment,only
,primary,endpoint,was,negative,conversion,rate,sarscov2,nucleic,acid,respiratory,pharyngeal,swab,days,7,after,randomization
,study,has,been,approved,ethics,committee,shanghai,public,health,clinical,center,registered,online,nct04261517
results,one,patient,hcq,group,developed,severe,treatment
,day,7,nucleic,acid,throat,swabs,was,negative,13,867
cases,hcq,group,14,933
cases,control,group,p005
,median,duration,hospitalization,virus,nucleic,acid,negative,conservation,was,4,19,days,hcq,group,is,comparable,control,group,2,14,days,z127,p005
,median,time,body,temperature,normalization,hcq,group,was,1,02,day,after,hospitalization,was,comparable,control,group,1,03,day
radiological,progression,was,shown,ct,images,5,cases,333,hcq,group,7,cases,467,control,group,patients,improvement,followup,examinations
four,cases,267,hcq,group,3,cases,20,control,group,had,transient,diarrhea,abnormal,liver,function,p005
,prognosis,covid19,moderate,patients,is,good
larger,sample,size,study,needed,investigate,effects,hcq,treatment,covid19
subsequent,research,determine,better,endpoint,fully,consider,feasibility,experiments,sample,size
triple,combination,interferon,beta1b,lopinavirritonavir,ribavirin,treatment,patients,admitted,hospital,covid19,openlabel,randomised,phase,2,trial
background,effective,antiviral,therapy,is,important,tackling,coronavirus,disease,2019,covid19,pandemic
,assessed,efficacy,safety,combined,interferon,beta1b,lopinavirritonavir,ribavirin,treating,patients,covid19
methods,was,multicentre,prospective,openlabel,randomised,phase,2,trial,adults,covid19,who,admitted,six,hospitals,hong,kong
patients,randomly,assigned,21,14day,combination,lopinavir,400,ritonavir,100,every,12,h,ribavirin,400,every,12,h,three,doses,8,million,international,units,interferon,beta1b,alternate,days,combination,group,14,days,lopinavir,400,ritonavir,100,every,12,h,control,group
,primary,endpoint,was,time,providing,nasopharyngeal,swab,negative,severe,acute,respiratory,syndrome,coronavirus,2,rtpcr,was,intentiontreat,population
,study,is,registered,clinicaltrialsgov
findings,feb,10,march,20,2020,127,patients,recruited,86,randomly,assigned,combination,group,41,assigned,control,group
,median,number,days,symptom,onset,start,study,treatment,was,5,days,iqr,37
,combination,group,had,shorter,median,time,start,study,treatment,negative,nasopharyngeal,swab,7,days,iqr,511,control,group,12,days,815,hazard,ratio,4,37,95,ci,1,8610,24,p0,0010
adverse,events,included,selflimited,nausea,diarrhoea,difference,two,groups
one,patient,control,group,discontinued,lopinavirritonavir,biochemical,hepatitis
,patients,died,study
interpretation,early,triple,antiviral,therapy,was,safe,superior,lopinavirritonavir,alone,alleviating,symptoms,shortening,duration,viral,shedding,hospital,stay,patients,mild,moderate,covid19
future,clinical,study,double,antiviral,therapy,interferon,beta1b,backbone,is,warranted
funding,shawfoundation,richard,carol,yu,tam,mak,mei,yin,sanming,project,medicine
imaging,features,mechanisms,novel,coronavirus,pneumonia,covid19,study,protocol,clinical,trial,spirit,compliant
introduction,novel,coronavirus,tentatively,designated,2019,novel,coronavirus,2019ncov,now,called,severe,acute,respiratory,syndrome,coronavirus,2,emerged,wuhan,china,end,2019,continues,expand
,february,11,2020,world,health,organization,who,named,disease,coronavirus,disease,2019,covid19
,february,28,who,increased,assessment,risk,spread,risk,impact,covid19,high,global,level
,covid19,poses,significant,threats,international,healthcomputed,tomography,ct,has,been,important,imaging,modality,assisting,diagnosis,management,patients,withcovid19
,retrospective,imaging,studies,have,reported,chest,ct,findings,covid19,past,2,months,suggesting,ct,findings,be,characteristic
,knowledge,has,been,prospective,multicentre,imaging,study,covid19,date,proposed,hypothesis,specific,ct,features,chest,ct,covid19,patients
,mechanism,ct,features,is,explicable,based,pathological,findings
objective,investigate,specific,ct,features,covid19,formation,mechanism,ct,features
method,study,is,prospective,multicenter,observational,study
,will,recruit,100,patients,covid19,55,hospitals
,patients,undergo,chest,ct,examination,same,scan,protocol
,distribution,morphology,lesions,chest,ct,clinical,data,will,be,recorded
,number,patients,will,be,pathologically,examined,after,permission,is,granted
,data,three,aspects,will,be,analyzed,synthetically
discussion,study,will,help,us,identify,chest,ct,features,covid19,mechanism
ethics,dissemination,retrospective,study,was,approved,biomedical,research,ethics,committee,west,china,hospital,sichuan,university,2020140
written,informed,consent,will,be,study,participants,prior,enrollment,study
,protect,privacy,participants,private,information,kept,anonymous
,results,will,be,published,peerreviewed,journal,will,be,disseminated,electronically,print,regardless,results
repurposing,chlorpromazine,treat,covid19,recovery,study
objectives,ongoing,covid19,pandemic,has,caused,approximately,2350000,infections,worldwide,killed,more,160000,individuals
,sainte,anne,hospital,ghu,paris,psychiatrie,neuroscience,paris,france,have,observed,lower,incidence,symptomatic,forms,covid19,patients,clinical,staff
,observation,led,us,hypothesize,psychotropic,drugs,have,prophylactic,action,against,sarscov2,protect,patients,symptomatic,virulent,forms,infection,psychotropic,drugs,have,documented,antiviral,properties
chlorpromazine,cpz,phenothiazine,derivative,is,known,antiviral,activity,via,inhibition,clathrinmediated,endocytosis
recent,vitro,studies,have,reported,cpz,exhibits,antimerscov,antisarscov1,activity
methods,context,recovery,study,aims,repurpose,cpz,molecule,excellent,tolerance,profile,high,biodistribution,saliva,lungs,brain
,hypothesize,cpz,reduce,unfavorable,course,covid19,infection,patients,requiring,respiratory,support,need,icu,care,reduce,contagiousness,sarscov2
,purpose,plan,pilot,multicenter,randomized,single,blind,controlled,phase,iii,therapeutic,trial,standard,treatment,vs,cpz,standard,treatment
conclusion,repurposing,cpz,antisarscov2,activity,offer,alternative,rapid,strategy,alleviate,infection,severity
,repurposing,strategy,avoids,numerous,developmental,experimental,steps,save,precious,time,rapidly,establish,anticovid19,therapy,wellknown,limited,easily,managed,side,effects
serological,differentiation,covid19,sars,infections
,response,coronavirus,disease,2019,covid19,outbreak,caused,sarscov2,virus,multiple,diagnostic,tests,required,globally,acute,disease,diagnosis,contact,tracing,monitoring,asymptomatic,infection,rates,assessing,herd,immunity
,pcr,remains,frontline,test,choice,acute,diagnostic,setting,serological,tests,urgently,needed,fulfil,other,requirements
unlike,pcr,tests,highly,specific,virus,crossreactivity,potentially,be,major,challenge,covid19,antibody,tests,considering,six,other,coronaviruses,known,infect,humans
,human,pathogens,sarscov,is,genetically,related,sarscov2,sharing,approximately,80,sequence,identity,belong,species,sars,related,coronavirus,sarsrcov,genus,betacoronavirus,family,coronaviridae
,study,developed,compared,performance,four,different,serological,tests,comprehensively,assess,crossreactivity,covid19,sars,patient,sera
,results,indicate,is,significant,crossreactivity,n,protein,sarscov,sarscov2,is,used
,s1,rbd,derived,spike,s,protein,offers,better,specificity
amongst,different,platforms,capture,elisa,performed,best
finally,sars,survivors,have,significant,level,antibodies,remaining,blood,17,years,after,infection
,discovered,antin,antibodies,waned,more,antirbd,antibodies,latter,is,known,play,more,important,role,providing,protective,immunity
,global,pandemic,covid19,cases,caused,infection,sarscov2,is,ongoing,approved,antiviral,intervention
,describe,effects,treatment,interferon,ifnalpha2b,cohort,confirmed,covid19,cases,wuhan,china
,uncontrolled,exploratory,study,77,adults,hospitalized,confirmed,covid19,treated,nebulized,ifnalpha2b,5,mu,bd,arbidol,200,td,combination,ifnalpha2b,plus,arbidol
serial,sarscov2,testing,along,hematological,measurements,including,cell,counts,blood,biochemistry,serum,cytokine,levels,temperature,blood,oxygen,saturation,levels,recorded,patient,hospital,stay
treatment,ifnalpha2b,arbidol,reduced,duration,detectable,virus,upper,respiratory,tract,parallel,reduced,duration,elevated,blood,levels,inflammatory,markers,il6,crp
,findings,suggest,ifnalpha2b,be,investigated,therapy,covid19,cases
,italian,multicenter,retrospectiveprospective,observational,study,neurological,manifestations,covid19,neurocovid
neurological,manifestations,covid19,have,been,described,single,case,reports,retrospective,scanty,case,series
,be,linked,potential,neurotropism,sarscov2,virus,previously,demonstrated,other,coronaviruses
,report,description,multicenter,retrospectiveprospective,observational,study,promoted,italian,society,neurology,sin,involving,italian,neurological,departments,who,will,consecutively,recruit,patients,neurological,symptoms,signs,occurred,onset,complication,covid19
hospitalized,patients,will,be,recruited,neurological,wards,covid,wards,latter,cases,will,be,referred,other,specialists,participant,neurologists
outpatients,clinical,signs,covid,neurological,manifestations,will,be,referred,participating,neurologists,primary,care,physicians
,comprehensive,data,collection,form,electronic,case,report,form,ecrf,will,register,possible,neurological,manifestations,involving,central,nervous,systems,peripheral,nerves,muscles,together,clinical,laboratory,including,cerebrospinal,fluid,available,imaging,neurological,neurophysiological,neuropsychological,data
,followup,hospital,discharge,hospitalized,patients,patients,after,3,6,months,is,planned
,believe,study,help,intercept,full,spectrum,neurological,manifestations,covid19,given,large,diffusion,national,level,provide,large,cohort,patients,available,future,more,focused,investigations
similar,observational,studies,be,proposed,international,level,better,define,neurological,involvement,covid19
,management,emergency,spinal,surgery,covid19,pandemic,italy
aims,current,pandemic,caused,covid19,is,biggest,challenge,national,health,systems,century
,medical,resources,allocated,treat,covid19,patients,noncovid19,medical,emergencies,still,need,be,treated,including,vertebral,fractures,spinal,cord,compression
,aim,paper,is,report,early,experience,organizational,protocol,emergency,spinal,surgery,currently,being,used,large,metropolitan,area,integrated,team,orthopaedic,surgeons,neurosurgeons
methods,organizational,model,is,presented,based,case,centralization,hub,hospitals,early,management,surgical,cases,reduce,hospital,stay
data,patients,admitted,emergency,spinal,surgery,beginning,outbreak,prospectively,collected,compared,data,patients,admitted,same,reason,same,time,span,previous,year,treated,same,integrated,team
results,total,19,patients,11,males,eight,females,mean,age,499,years,14,83,admitted,vertebral,fracture,spinal,cord,compression,19day,period,compared,ten,admitted,previous,year
,mean,time,admission,surgery,was,17,days,lower,68,days,previous,year,p,0001
conclusion,structural,organization,management,protocol,describe,allowed,us,reduce,time,surgery,ultimately,hospital,stay,thereby,maximizing,already,stretched,medical,resources,available
,hope,early,experience,be,value,medical,communities,will,soon,be,same,emergency,situation
cite,article,bone,joint,j,2020102b616
effects,progressive,muscle,relaxation,anxiety,sleep,quality,patients,covid19
background,patients,coronavirus,disease,2019covid19,will,experience,high,levels,anxiety,low,sleep,quality,isolation,treatment
,sleepimproving,drugs,inhibit,respiratory,system,worsen,condition
prolonged,bedside,instruction,increase,risk,medical,infections
objective,investigate,effect,progressive,muscle,relaxation,anxiety,sleep,quality,covid19
methods,randomized,controlled,clinical,trial,total,51,patients,who,entered,isolation,ward,included,study,randomly,divided,experimental,control,groups
,experimental,group,used,progressive,muscle,relaxation,pmr,technology,30,min,per,day,5,consecutive,days
,period,control,group,received,only,routine,care,treatment
,after,intervention,spielberger,statetrait,anxiety,scale,stai,sleep,state,selfrating,scale,srss,used,measure,record,patient,anxiety,sleep,quality
finally,data,analysis,was,performed,spss,250,software
results,average,anxiety,score,stai,intervention,was,not,statistically,significant,p,0730,average,anxiety,score,after,intervention,was,statistically,significant,p,0001
,average,sleep,quality,score,srss,two,groups,intervention,was,not,statistically,significant,p,0838,was,statistically,significant,after,intervention,p,0001
conclusion,progressive,muscle,relaxation,auxiliary,method,reduce,anxiety,improve,sleep,quality,patients,covid19
efficacy,internetbased,integrated,intervention,depression,anxiety,symptoms,patients,covid19
public,health,crises,outbreak,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,dec,2019,widely,acknowledged,severe,traumatic,events,impose,threats,not,only,physical,concerns,psychological,distress,infected,patients
,designed,internetbased,integrated,intervention,evaluated,efficacy,depression,anxiety,symptoms,patients,infected,sarscov2
exosomes,derived,bone,marrow,mesenchymal,stem,cells,treatment,severe,covid19
,prospective,nonrandomized,openlabel,cohort,study,addresses,safety,efficacy,exosomes,exoflo,derived,allogeneic,bone,marrow,mesenchymal,stem,cells,treatment,severe,covid19
,april,2020,exoflo,was,provided,24,sarscov2,pcr,positive,patients,single,hospital,center,whom,met,criteria,severe,covid19,well,moderate,severe,acute,respiratory,distress,syndrome,ards
patients,received,single,15,intravenous,dose,exoflo,evaluated,safety,efficacy,day,114,posttreatment
,safety,endpoints,met,adverse,events,observed,72,hours,exoflo,administration
,survival,rate,83,was,observed
1724,71,patients,recovered,324,13,remained,critically,ill,though,stable,424,16,expired,reasons,unrelated,treatment
,after,one,treatment,patients,clinical,status,oxygenation,improved,average,pao2fio2,ratio,increase,192,p,0001
laboratory,values,revealed,significant,improvements,absolute,neutrophil,count,mean,reduction,32,pvalue,0001,lymphopenia,average,cd3,cd4,cd8,lymphocyte,counts,increasing,46,p,005,45,p,005,46,p,0001,respectively
likewise,acute,phase,reactants,declined,mean,creactive,protein,crp,ferritin,ddimer,reduction,77,p,001
,conclusion,safety,profile,capacity,restore,oxygenation,downregulate,cytokine,storm,reconstitute,immunity,exoflo,is,promising,therapeutic,candidate,severe,covid19
future,rcts,needed,determine,exoflo,therapeutic,potential
neutrophillymphocyte,ratio,predictive,biomarker,moderatesevere,ards,severe,covid19,patients
effect,hydroxychloroquine,covid19,prevention,cancer,patients,undergoing,treatment,structured,summary,study,protocol,randomised,controlled,trial
objectives,study,investigate,effect,hydroxychloroquine,prevention,novel,coronavirus,disease,covid19,cancer,patients,being,treated
trial,design,is,multicentre,twoarm,parallelgroup,tripleblind,phase,23,randomised,controlled,trial
participants,patients,over,age,15,5,types,cancer,included,study
patients,acute,lymphoid,myeloid,leukemias,first,line,treated,curative,intent,patients,highgrade,nonhodgkins,lymphoma,treated,leukemia,protocols,patients,nonmetastatic,breast,colon,cancer,first,line,treatment,will,enter,study
,exclusion,criteria,will,include,known,sensitivity,hydroxychloroquine,weight,below,35,kilograms,history,retinopathy,history,cardiac,disease,acute,respiratory,tract,infection,last,2,months,having,covid19,first,two,weeks,entering,trial,having,diabetes,mellitus,having,immunosuppressive,disease,other,cancer,having,chronic,pulmonary,disease,taking,immunosuppressant,drug,other,chemotherapeutic,agents,current,cancer
,study,is,performed,five,academic,centres,affiliated,mashhad,university,medical,sciences,mashhad,iran
intervention,comparator,patients,randomly,assigned,two,groups,one,being,given,hydroxychloroquine,other,is,given,placebo
,two,months,treatment,two,groups,treated,hydroxychloroquine,amin,pharmaceutical,company,isfahan,iran,placebo,identical,terms,shape,colour,smell,single,200,tablet,every,other,day
patients,will,be,monitored,covid19,symptoms,followup,period
,signs,symptoms,occur,fever,cough,shortness,breath,will,be,examined,investigated,highresolution,computed,tomography,ct,scan,lungs,covid19,specific,igm,igg,antibody,assay,nucleic,acid,amplification,test,nat,sarscov2,virus
main,outcomes,primary,end,point,study,is,investigate,incidence,covid19,patients,being,treated,cancer,over,2month,period
randomisation,randomisation,will,be,performed,randomly,permuted,blocks
,online,website,wwwrandomizationcom
,randomization,sequence,will,be,produced,quadruple,blocks
,allocation,ratio,intervention,control,groups,is,11
blinding,masking,participants,caregivers,not,know,whether,patient,is,intervention,control,group
,outcome,assessor,data,analyst,blinded,group,assignment
numbers,be,randomised,sample,size,calculated,total,sample,size,is,60,patients,30,patients,group
trial,status,trial,began,april,14,2020,recruitment,is,ongoing
recruitment,is,anticipated,be,completed,june,14,2020,has,been,change,study,protocol,approval,protocol,version,1,was,approved,april,12,2020
trial,registration,trial,has,been,registered,title,effect,hydroxychloroquine,novel,coronavirus,disease,covid19,prevention,cancer,patients,under,treatment,iranian,registry,clinical,trials,irct,code,irct20200405046958n1,httpswwwirctirtrial46946
full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
ruxolitinib,treatment,severe,coronavirus,disease,2019,covid19,multicenter,singleblind,randomized,controlled,trial
background,accumulating,evidence,proposed,jak,inhibitors,therapeutic,targets,warranting,rapid,investigation
objective,study,evaluated,efficacy,safety,ruxolitinib,janusassociated,kinase,jak12,inhibitor,covid19
methods,conducted,prospective,multicenter,singleblind,randomized,controlled,phase,ii,trial,involving,patients,severe,covid19
results,fortythree,patients,randomly,assigned,11,receive,ruxolitinib,plus,soc,treatment,22,patients,placebo,based,soc,treatment,21,patients
after,exclusion,2,patients,1,ineligible,1,consent,withdrawn,ruxolitinib,group,20,patients,intervention,group,21,patients,control,group,included,study
treatment,ruxolitinib,plus,soc,was,not,associated,accelerated,clinical,improvement,severe,patients,covid19,ruxolitinib,recipients,had,numerically,faster,clinical,improvement
eighteen,90,patients,ruxolitinib,group,ct,improvement,d14,compared,13,619
patients,control,group,p,00495
three,patients,control,group,died,respiratory,failure,143,mortality,d28,patients,died,ruxolitinib,group
ruxolitinib,was,well,tolerated,low,toxicities,new,safety,signals
levels,7,cytokines,decreased,ruxolitinib,group,comparison,control,group
,statistical,difference,was,observed,ruxolitinib,recipients,had,numerically,faster,clinical,improvement
significant,chest,ct,improvement,faster,recovery,lymphopenia,favorable,sideeffect,profile,ruxolitinib,group,encouraging,informative,future,trials,test,efficacy,ruxolitinib,larger,population
,trial,is,registered,wwwchictrorgcn,chictropn2000029580
hydroxychloroquine,patients,mild,moderate,coronavirus,disease,2019,open,label,randomised,controlled,trial
objective,assess,efficacy,safety,hydroxychloroquine,plus,standard,care,compared,standard,care,alone,adults,coronavirus,disease,2019,covid19
design,multicentre,open,label,randomised,controlled,trial
setting,16,government,designated,covid19,treatment,centres,china,11,29,february,2020
participants,150,patients,admitted,hospital,laboratory,confirmed,covid19,included,intention,treat,analysis,75,patients,assigned,hydroxychloroquine,plus,standard,care,75,standard,care,alone
interventions,hydroxychloroquine,administrated,loading,dose,1200,daily,three,days,followed,maintenance,dose,800,daily,total,treatment,duration,two,three,weeks,patients,mild,moderate,severe,disease,respectively
main,outcome,measure,negative,conversion,severe,acute,respiratory,syndrome,coronavirus,2,28,days,analysed,according,intention,treat,principle
adverse,events,analysed,safety,population,hydroxychloroquine,recipients,participants,who,received,least,one,dose,hydroxychloroquine,hydroxychloroquine,nonrecipients,managed,standard,care,alone
results,150,patients,148,had,mild,moderate,disease,two,had,severe,disease
,mean,duration,symptom,onset,randomisation,was,166,sd,105,range,341,days
,total,109,73,patients,56,standard,care,53,standard,care,plus,hydroxychloroquine,had,negative,conversion,well,28,days,remaining,41,27,patients,19,standard,care,22,standard,care,plus,hydroxychloroquine,censored,did,not,reach,negative,conversion,virus
,probability,negative,conversion,28,days,standard,care,plus,hydroxychloroquine,group,was,854,95,confidence,interval,738,938,similar,standard,care,group,813,712,896
,difference,groups,was,41,95,confidence,interval,103,185
,safety,population,adverse,events,recorded,780,9,hydroxychloroquine,nonrecipients,2170,30,hydroxychloroquine,recipients
,common,adverse,event,hydroxychloroquine,recipients,was,diarrhoea,reported,770,10,patients
two,hydroxychloroquine,recipients,reported,serious,adverse,events
,administration,hydroxychloroquine,did,not,result,higher,probability,negative,conversion,standard,care,alone,patients,admitted,hospital,persistent,mild,moderate,covid19
adverse,events,higher,hydroxychloroquine,recipients,nonrecipients
effect,high,vs,low,doses,chloroquine,diphosphate,adjunctive,therapy,patients,hospitalized,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,infection,randomized,clinical,trial
importance,is,specific,antiviral,therapy,recommended,coronavirus,disease,2019,covid19
,vitro,studies,indicate,antiviral,effect,chloroquine,diphosphate,cq,requires,high,concentration,drug
objective,evaluate,safety,efficacy,2,cq,dosages,patients,severe,covid19
design,setting,participants,parallel,doublemasked,randomized,phase,iib,clinical,trial,81,adult,patients,who,hospitalized,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,infection,was,conducted,march,23,april,5,2020,tertiary,care,facility,manaus,brazilian,amazon
interventions,patients,allocated,receive,highdosage,cq,ie,600,cq,twice,daily,10,days,lowdosage,cq,ie,450,twice,daily,day,1,once,daily,4,days
main,outcomes,measures,primary,outcome,was,reduction,lethality,least,50,highdosage,group,compared,lowdosage,group
data,presented,refer,primarily,safety,lethality,outcomes,treatment,day,13
secondary,end,points,included,participant,clinical,status,laboratory,examinations,electrocardiogram,results
outcomes,will,be,presented,day,28
viral,respiratory,secretion,rna,detection,was,performed,days,0,4,results,out,predefined,sample,size,440,patients,81,enrolled,41,506,highdosage,group,40,494,lowdosage,group
enrolled,patients,had,mean,sd,age,511,139,years,60,753,men
older,age,mean,sd,age,547,137,years,vs,474,133,years,more,heart,disease,5,28,179
vs,0,seen,highdose,group
viral,rna,was,detected,31,40,775,31,41,756,patients,lowdosage,highdosage,groups,respectively
lethality,until,day,13,was,390,highdosage,group,16,41,150,lowdosage,group,6,40
,highdosage,group,presented,more,instance,qtc,interval,greater,500,milliseconds,7,37,189
compared,lowdosage,group,4,36,111
respiratory,secretion,day,4,was,negative,only,6,27,patients,222
,relevance,preliminary,findings,study,suggest,higher,cq,dosage,not,be,recommended,critically,ill,patients,covid19,potential,safety,hazards,taken,concurrently,azithromycin,oseltamivir
,findings,cannot,be,extrapolated,patients,nonsevere,covid19
safety,efficacy,assessment,allogeneic,human,dental,pulp,stem,cells,treat,patients,severe,covid19,structured,summary,study,protocol,randomized,controlled,trial,phase,ii
objectives,assess,safety,therapeutic,effects,allogeneic,human,dental,pulp,stem,cells,dpscs,treating,severe,pneumonia,caused,covid19
trial,design,is,single,centre,two,arm,ratio,11,triple,blinded,randomized,placebocontrolled,parallel,group,clinical,trial
participants,twenty,serious,covid19,cases,will,be,enrolled,trial,april,6th,december,31st,2020
inclusion,criteria,hospitalised,patients,renmin,hospital,wuhan,university,satisfy,criteria,below,1adults,aged,1865,years2voluntarily,participate,clinical,trial,sign,informed,consent,form,have,consent,legal,representative3diagnosed
,severe,pneumonia,covid19,nucleic,acid,test,sarscov2,positive,respiratory,distress,respiratory,rate,30,times,min,hypoxia,resting,oxygen,saturation,93,arterial,partial,pressure,oxygen,oxygen,concentration,300,mmhg4covid19
featured,lung,lesions,chest,xray,image
exclusion,criteria,patients,will,be,excluded,study,meet,following,criteria
1patients,have,received,other,experimental,treatment,covid19,last,30,days2patients,have,severe,liver,condition,eg,child,pugh,score,c,ast,5,times,upper,limit3patients,severe,renal,insufficiency,estimated,glomerular,filtration,rate,30ml,min173
m2,patients,receiving,continuous,renal,replacement,therapy,hemodialysis,peritoneal,dialysis4patients,who,coinfected,hiv,hepatitis,b,tuberculosis,influenza,virus,adenovirus,other,respiratory,infection,viruses5female,patients,who,have,sexual,protection,last,30,days,prior,screening,assessment6pregnant,lactating,women,women,estrogen,contraception7patients,who,planning,become,pregnant,study,period,6,months,after,end,study,period8other,conditions,researchers,consider,not,suitable,participating,clinical,trial
intervention,comparator,will,be,two,study,groups,experimental,control
,will,receive,necessary,routine,treatment,covid19
,experimental,group,will,receive,intravenous,injection,dental,pulp,stem,cells,suspension,30x107,human,dpscs,30ml,saline,solution,day,1,4,7,control,group,will,receive,equal,amount,saline,placebo,same,days
clinical,laboratory,observations,will,be,performed,analysis,period,28,days,case,commencement,study
primary,outcome,primary,outcome,is,time,clinical,improvement,ttci
,definition,ttci,is,time,days,takes,downgrade,two,levels,following,six,ordered,grades,grade,1,discharge,grade,6,death,clinical,state,admission,start,study,treatments,hdpscs,placebo
six,grades,ordered,variables,gradedescriptiongrade,1discharged,patientgrade,2hospitalized,oxygen,supplementgrade,3hospitalized,oxygen,supplement,is,required,niv,hfnc,is,not,requiredgrade,4hospitalized,intensive,care,unit,niv,hfnc,treatment,is,requiredgrade,5hospitalized,intensive,care,unit,requiring,ecmo,imvgrade,6death
abbreviations,niv,noninvasive,mechanical,ventilation,hfnc,highflow,nasal,catheter,imv,invasive,mechanical,ventilation
2,secondary,outcomes,21,vital,signs,heart,rate,blood,pressure,systolic,blood,pressure,diastolic,blood,pressure
,screening,period,hospitalization,every,day,additional,time,points,d1,d4,d7,30min,injection,2h,30min,24h,30min,after,injection,followup,period,d90,3,days
22,laboratory,examinations,screening,period,30,minutes,d1,d4,d7,infusion,2h,30min,24h,30min,after,end,infusion,d10,d14,d28,hospitalization,discharge,day,followup,period,d90,3,days
23,blood,routine,white,blood,cells,neutrophils,lymphocytes,monocytes,eosinophils,basophils,neutrophils,lymphocytes,monocytes,eosinophils,acidic,granulocyte,count,basophil,count,red,blood,cell,hemoglobin,hematocrit,average,volume,red,blood,cells,average,red,blood,cell,hb,content,average,red,blood,cell,hb,concentration,rdw,standard,deviation,rdw,coefficient,variation,platelet,count,platelet,specific,platelet,average,volume,platelet,distribution,width,large,platelets,24,liver,kidney,function,tests,alanine,aminotransferase,aspartate,aminotransferase,alkaline,phosphatase,gammaglutamyl,transferase,prealbumin,total,protein,albumin,globulin,white,globule,ratio,total,bilirubin,direct,bilirubin,cholinesterase,urea,creatinine,total,carbon,dioxide,uric,acid,glucose,potassium,sodium,chlorine,calcium,corrected,calcium,magnesium,phosphorus,calcium,phosphorus,product,anion,gap,penetration,pressure,total,cholesterol,triacylglycerol,high,density,lipoprotein,cholesterol,low,density,lipoprotein,cholesterol,lipoprotein,creatine,kinase,lactate,dehydrogenase,estimated,glomerular,filtration,rate
25,inflammation,indicators,hypersensitive,creactive,protein,serum,amyloid,saa,26,infectious,disease,testing,hepatitis,b,hbsag,hbsab,hbeag,hbeab,hbcab,hepatitis,c,antihcv,aids,hivcombin,syphilis,antitp,cytomegalovirus,cmvigm,cytomegalovirus,cmvigg,only,screening,period,followup,period,d90,3,27,immunological,testing,collect,peripheral,blood,detect,phenotype,t,lymphocyte,b,lymphocyte,natural,killer,cell,macrophage,neutrophil,flow,cytometry
collect,peripheral,blood,detect,gene,profile,mononuclear,cells,singlecell,analyses
collect,peripheral,blood,serum,detect,immunoglobulin,changes,iga,igg,igm,total,ige,collect,peripheral,blood,serum,explore,changes,cytokines,th1,cytokines,il1,beta,il2,tnf,itngamma,th2,cytokines,il4,il6,il,10
28,pregnancy,test,blood,betahcg,female,subjects,menopause,examined,screening,period,followup,period,d90,3,29,urine,routine,color,clarity,urine,sugar,bilirubin,ketone,bodies,specific,gravity,ph,urobilinogen,nitrite,protein,occult,blood,leukocyte,enzymes,red,blood,cells,white,blood,cells,epithelial,cells,nonsquamous,epithelial,cells,transparent,cast,pathological,cast,crystal,fungus,210,stool,routine,color,traits,white,blood,cells,red,blood,cells,fat,globules,eggs,parasites,fungi,occult,blood,chemical,method,occult,blood,immune,method,transferrin,2h,30min,after,injection,not,detected,after,discharge
randomization,block,randomization,method,will,be,applied,computer,allocate,participants,experimental,control,groups
blinding,masking,participants,outcomes,assessors,investigators,including,personnel,laboratory,imaging,department,who,issue,sample,report,image,observations,will,be,blinded
injections,cell,suspension,saline,will,be,coded,accordance,patients,randomisation,group
,blind,strategy,is,kept,investigator,who,not,deliver,medical,care,assess,primary,outcome,results
numbers,be,randomized,sample,size,twenty,participants,will,be,randomized,experimental,control,groups,10,per,group
trial,status,protocol,version,number,hdpsccovid2019022020,version,20,march,13,2020
patients,screening,commenced,16th,april,estimated,date,recruitment,final,participants,will,be,around,end,july
trial,registration,registration,world,health,organization,trial,registry,chictr2000031319,march,272020
identifier,nct04336254,april,7,2020,other,study,id,numbers,hdpsccovid2019022020,full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
application,caredose,4d,combined,karl,3d,technology,low,dose,computed,tomography,followup,covid19
background,coronavirus,disease,2019,covid19,is,highly,infectious,disease,caused,new,coronavirus
previous,studies,have,shown,chest,ct,examination,plays,important,role,diagnosis,monitoring,covid19
,patients,covid19,had,low,white,blood,cell,counts,reduced,lymphocyte,ratios
multiple,ct,examinations,cause,radiation,damages,well,increase,apoptosis,peripheral,blood,lymphocytes
,new,lowdose,ct,method,be,developed,regular,ct,aggravate,disease
method,sixty,cases,randomly,divided,study,group,n,30,control,group,n,30
,lung,window,was,reconstructed,karl,3d,iterative,technique,study,group
,image,quality,was,subjectively,evaluated,two,senior,chest,group,diagnostic,physicians,5point,doubleblind,method
,value,ct,measurement,standard,deviation,sd,was,used,objective,evaluation,criteria
,volume,ct,dose,index,ctdivol,dose,length,product,dlp,effective,dose,ed,two,groups,compared,analyzed,statistically
result,was,significant,difference,occurrence,rates,ground,glass,opacities,consolidation,crazypaving,pattern,fiber,cable,shadow,axial,interstitial,thickening,study,group,control,group,p,005
,addition,significant,difference,was,subjective,score,image,quality,image,noise,level,sd,two,groups,p,005
,significant,differences,was,ctdivol,dlp,ed,study,group,control,group,p,005
,effective,dose,study,group,was,reduced,76,compared,control,group
conclusion,caredose,4d,lowdose,scanning,combined,karl,3d,iterative,reconstruction,technology,not,only,greatly,reduce,radiation,dose,provide,images,meet,diagnostic,criteria,covid19,be,used,routine,method,followup,covid19,patients
efficacy,chloroquine,versus,lopinavirritonavir,mildgeneral,covid19,infection,prospective,openlabel,multicenter,randomized,controlled,clinical,study
background,outbreak,covid19,caused,sarscov2,is,serious,effective,antiviral,treatment,has,yet,been,confirmed
,adage,old,drug,new,trick,context,suggest,important,therapeutic,potential,existing,drugs
,lopinavirritonavir,treatment,recommended,fifth,edition,treatment,plan,china,only,help,improve,minority,throatswab,nucleicacid,results,315,hospitals
,previous,use,chloroquine,treat,patients,covid19,infection,improvement,more,throatswab,nucleicacid,results,510,use,lopinavirritonavir
methodsdesign,is,prospective,openlabel,randomized,controlled,multicenter,clinical,study
,study,consists,three,phases,screening,period,treatment,period,more,10,days,followup,period,participant
participants,covid19,infection,who,eligible,selection,study,will,be,randomly,allocated,trial,group,control,group
,control,group,will,be,given,lopinavirritonavir,treatment,more,10,days
,trial,group,will,be,given,chloroquine,phosphate,treatment,more,10,days
,primary,outcome,is,clinical,recovery,time,more,28,days,after,completion,therapy,followup
,secondary,outcomes,include,rate,treatment,success,after,completion,therapy,followup,time,treatment,success,after,more,28,days,rate,serious,adverse,events,completion,therapy,followup,time,return,normal,temperature,calculated,onset,illness,completion,therapy,followup
comparisons,will,be,performed,twosided,tests,statistical,significance,level,5
discussion,experiment,reveal,efficacy,safety,chloroquine,versus,lopinavirritonavir,patients,mildgeneral,covid19,infection
,new,treatment,including,chloroquine,shows,higher,rate,throatswab,sarscov2,realtime,fluorescent,reverse,transcription,polymerase,chain,reaction,rtpcr,negativity,is,safe,be,tested,future,covid19,treatment
trial,registration,chinese,clinical,trial,registry,id,chictr2000029741
effect,high,vs,low,doses,chloroquine,diphosphate,adjunctive,therapy,patients,hospitalized,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,infection,randomized,clinical,trial
importance,is,specific,antiviral,therapy,recommended,coronavirus,disease,2019,covid19
,vitro,studies,indicate,antiviral,effect,chloroquine,diphosphate,cq,requires,high,concentration,drug
objective,evaluate,safety,efficacy,2,cq,dosages,patients,severe,covid19
design,setting,participants,parallel,doublemasked,randomized,phase,iib,clinical,trial,81,adult,patients,who,hospitalized,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2,infection,was,conducted,march,23,april,5,2020,tertiary,care,facility,manaus,brazilian,amazon
interventions,patients,allocated,receive,highdosage,cq,ie,600,cq,twice,daily,10,days,lowdosage,cq,ie,450,twice,daily,day,1,once,daily,4,days
main,outcomes,measures,primary,outcome,was,reduction,lethality,least,50,highdosage,group,compared,lowdosage,group
data,presented,refer,primarily,safety,lethality,outcomes,treatment,day,13
secondary,end,points,included,participant,clinical,status,laboratory,examinations,electrocardiogram,results
outcomes,will,be,presented,day,28
viral,respiratory,secretion,rna,detection,was,performed,days,0,4,results,out,predefined,sample,size,440,patients,81,enrolled,41,506,highdosage,group,40,494,lowdosage,group
enrolled,patients,had,mean,sd,age,511,139,years,60,753,men
older,age,mean,sd,age,547,137,years,vs,474,133,years,more,heart,disease,5,28,179
vs,0,seen,highdose,group
viral,rna,was,detected,31,40,775,31,41,756,patients,lowdosage,highdosage,groups,respectively
lethality,until,day,13,was,390,highdosage,group,16,41,150,lowdosage,group,6,40
,highdosage,group,presented,more,instance,qtc,interval,greater,500,milliseconds,7,37,189
compared,lowdosage,group,4,36,111
respiratory,secretion,day,4,was,negative,only,6,27,patients,222
,relevance,preliminary,findings,study,suggest,higher,cq,dosage,not,be,recommended,critically,ill,patients,covid19,potential,safety,hazards,taken,concurrently,azithromycin,oseltamivir
,findings,cannot,be,extrapolated,patients,nonsevere,covid19
significance,operation,mode,moxibustion,intervention,group,under,quarantine,after,close,contact,covid19
,base,idea,traditional,chinese,medicine,disease,prevention,mode,protocol,moxibustion,intervention,group,under,quarantine,after,close,contact,coronavirus,disease,2019,covid19,explored
,group,under,quarantine,after,close,contact,covid19,was,taken,subjects
,noncontact,physicianpatient,communication,network,platform,codeveloped,china,association,acupuncturemoxibustion,hunan,provincial,association,acupuncturemoxibustion,data,center,china,academy,chinese,medical,sciences,yuge,medicine,company,exploratory,randomized,controlled,trial,was,designed
,total,100,cases,included,randomized,moxibustion,group,conventional,intervention,group,50,cases,one
,moxibustion,group,moxibustion,intervention,was,used
,conventional,intervention,group,conventional,observation,was,adopted,moxibusiton,intervention,applied
,outcomes,included,symptoms,changes,eg
anxiety,emotional,disturbance,fatigue,headache,diarrhea,well,whether,quarantine,release,case,confirmed,not,etc
,results,evaluated,intervention,14,days,intervention,2,weeks,after,intervention,separately
,research,base,internet,plus,technology,internet,communication,platform,adopted,mobile,phone,wechat,app,was,implement,subject,screen,random,allocation,instruction,moxibustion,intervention,well,quality,control,patients,diary,data,collection
,is,anticipated,significance,implementation,mode,moxibustion,intervention,be,assessed,preliminarily,group,under,quarantine,after,close,contact,covid19
effect,colchicine,vs,standard,care,cardiac,inflammatory,biomarkers,clinical,outcomes,patients,hospitalized,coronavirus,disease,2019,grecco19,randomized,clinical,trial
importance,severe,acute,respiratory,syndrome,coronavirus,2,infection,has,evolved,global,pandemic
lowdose,colchicine,combines,antiinflammatory,action,favorable,safety,profile
objective,evaluate,effect,treatment,colchicine,cardiac,inflammatory,biomarkers,clinical,outcomes,patients,hospitalized,coronavirus,disease,2019,covid19
design,setting,participants,prospective,openlabel,randomized,clinical,trial,greek,study,effects,colchicine,covid19,complications,prevention,105,patients,hospitalized,covid19,randomized,11,allocation,april,3,april,27,2020,standard,medical,treatment,colchicine,standard,medical,treatment
,study,took,place,16,tertiary,hospitals,greece
intervention,colchicine,administration,15,loading,dose,followed,05,after,60,min,maintenance,doses,05,twice,daily,standard,medical,treatment,long,3,weeks
main,outcomes,measures,primary,end,points,1,maximum,highsensitivity,cardiac,troponin,level,2,time,creactive,protein,reach,more,3,times,upper,reference,limit,3,time,deterioration,2,points,7grade,clinical,status,scale,ranging,able,resume,normal,activities,death
secondary,end,points,1,percentage,participants,requiring,mechanical,ventilation,2,cause,mortality,3,number,type,severity,seriousness,adverse,events
,primary,efficacy,analysis,was,performed,intentiontreat,basis
results,total,105,patients,evaluated,61,581,men,median,interquartile,range,age,64,5476,years,50,476
randomized,control,group,55,524,colchicine,group
median,interquartile,range,peak,highsensitivity,cardiac,troponin,values,00112,0004300093,ng,control,group,0008,000400135,ng,colchicine,group,p,34
median,interquartile,range,maximum,creactive,protein,levels,45,1489
,clinical,primary,end,point,rate,was,140,control,group,7,50,patients,18,colchicine,group,1,55,patients,odds,ratio,011,95,ci,001096
mean,sd,eventfree,survival,time,was,186,083,days,control,group,vs,207,031,colchicine,group,log,rank,p,03
adverse,events,similar,2,groups,except,diarrhea,was,more,frequent,colchicine,group,control,group,25,patients,455,vs,9,patients,180
,relevance,randomized,clinical,trial,participants,who,received,colchicine,had,statistically,improved,time,clinical,deterioration
,significant,differences,highsensitivity,cardiac,troponin,creactive,protein,levels
,findings,be,interpreted,caution
infusion,convalescent,plasma,is,associated,clinical,improvement,critically,ill,patients,covid19,pilot,study
background,ideal,treatment,coronavirus,disease,covid19,has,yet,be,defined,convalescent,plasma,copla,has,been,successfully,employed
objective,objective,study,was,study,safety,outcomes,administration,copla,individuals,severe,covid19,academic,medical,center
methods,ten,patients,prospectively,treated,plasma,covid19,convalescent,donors
results,over,8,days,sequential,organ,failure,assessment,score,dropped,patients,3,15,p,0014,kirby,index,pao2fio2,score,increased,124,255,p,00001,body,temperature,decreased,381,369,c,p,00058,ferritin,levels,dropped,17366,10618,ng,p,00001
chest,xrays,improved,710,cases,610,computerized,tomography,scans,revealed,improvement,lung,injury
decreases,creactive,protein,ddimer,levels,observed
three,five,patients,mechanical,ventilation,support,be,extubated,nine,transferred,conventional,hospital,floors,six,sent,home,two,patients,died
,administration,copla,had,side,effects,24day,survival,was,77
,other,treatments,administered,patients,result,data,difficult,interpret,seems,addition,copla,improved,pulmonary,function
repurposed,immunomodulatory,drugs,covid19,preicu,patients,multiarm,therapeutic,study,preicu,patients,admitted,covid19,repurposed,drugs,tacticr,structured,summary,study,protocol,randomised,controlled,trial
objectives,determine,specific,immunomodulatory,intervention,reduces,progression,covid19related,disease,organ,failure,death,compared,standard,care,soc
trial,design,randomised,parallel,3arm,111,ratio,openlabel,phase,iv,platform,trial,immunomodulatory,therapies,patients,late,stage,1,stage,2,covid19related,disease,diagnosis,based,positive,assay,high,suspicion,covid19,infection,clinical,radiological,assessment
participants,patients,aged,18,over,clinical,picture,strongly,suggestive,covid19related,disease,positive,covid19,test,risk,count,defined,below,3,3,risk,count,includes,radiographic,severity,score,3
,risk,count,is,calculated,following,features,admission,1,point,radiographic,severity,score,3,male,gender,nonwhite,ethnicity,diabetes,hypertension,neutrophils,80,x109l,age,40,years,crp,40,l
patients,be,considered,appropriate,subject,intervention,immunomodulatory,therapies,opinion,investigator,be,able,be,maintained,venous,thromboembolism,prophylaxis,inpatient,dosing,period,according,local,guidelines
,complete,inclusion,exclusion,criteria,detailed,additional,file,1,be,fulfilled
patients,will,be,enrolled,prior,need,invasive,mechanical,ventilation,cardiac,renal,support
participants,will,be,recruited,across,multiple,centres,including,initially,cambridge,university,hospitals,nhs,foundation,trust,kings,college,hospital,nhs,foundation,trust,guys,st,thomas,nhs,foundation,trust,university,hospital,wales,gloucestershire,royal,hospitals,nhs,foundation,trust,royal,wolverhampton,nhs,trust
intervention,comparator,active,comparator,arm,will,be,compared,against,standard,care,soc
,immunomodulatory,drugs,selected,panel,licenced,candidates,drug,evaluation,committee,considered,potential,efficacy,potential,toxicity,scalability,novelty,strategy
,initial,active,arms,comprise,baricitinib,ravulizumab
baricitinib,will,be,given,4,orally,once,daily,od,days,114,until,day,discharge
,dose,will,be,reduced,2,od,patients,aged,75,years,estimated,cockcroft,gault,creatinine,clearance,3060,min
ravulizumab,will,be,administered,intravenously,once,according,licensed,weightbased,dosing,regimen,see,additional,file,1
,active,arm,will,be,compared,standard,care,alone
,comparisons,will,be,active,arms,platform,trial
main,outcomes,primary,outcome,is,incidence,baseline,up,day,14,one,events,whichever,comes,first,death,invasive,mechanical,ventilation,extra,corporeal,membrane,oxygenation,cardiovascular,organ,support,inotropes,balloon,pump,renal,failure,estimated,cockcroft,gault,creatinine,clearance,15mlmin
randomisation,eligible,patients,will,be,randomised,central,webbased,randomisation,service,sealed,envelope,111,ratio,stratified,site,one,treatment,arms,soc
blinding,masking,is,openlabel,trial
data,analysis,will,not,be,blinded
numbers,be,randomised,sample,size,is,fixed,sample,size,study
serial,interim,analyses,will,be,triggered,independent,data,monitoring,committee,idmc,including,analysis,after,125,patients,recruited,arm,375,total,assuming,3,arms
additional,interim,analyses,projected,after,229,patients,per,arm,potentially,after,469,per,arm,additional,analyses,be,triggered,idmc
trial,status,tacticr,protocol,version,number,20,date,20,2020,recruitment,began,7,2020,end,trial,will,be,date,18,months,after,last,patients,last,visit
,recruitment,end,date,cannot,yet,be,accurately,predicted
trial,registration,registered,eu,clinical,trials,register,eudract,number,202000135422,registered,6,2020,was,registered,clinicaltrialsgov
,nct04390464,isrctn,isrctn11188345,full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
ph,acute,lymphoblastic,leukaemia,italy,covid19,pandemic
,recent,spread,covid19,infection,has,raised,important,questions,haematology,community,best,manage,treat,patients,haematological,malignancies,particularly,acute,leukaemias
italy,has,witnessed,dramatic,raise,infections,death,rates,has,hit,particular,certain,areas,populated,northern,regions,country,lombardia,veneto,piemonte,emilia,romagna
,nationwide,campus,programme,last,week,march,sent,questionnaire,addressing,different,issues,related,management,adult,patients,covid19,pandemic,40,haematology,centres,located,entire,territory
triiodothyronine,treatment,critically,ill,patients,covid19,infection,structured,summary,study,protocol,randomised,controlled,trial
objectives,tissue,hypoxia,is,main,cause,multiorgan,dysfunction,sepsis
,effective,pharmacological,treatments,combat,sepsisinduced,tissue,hypoxia,not,available
emerging,experimental,clinical,evidence,reveals,evolutionary,conserved,action,thyroid,hormone,th,adapt,injured,tissue,hypoxic,conditions,via,action,p38,mapk,akt,signaling,pathways
,addition,th,has,favorable,effects,immune,system,viral,load,infected,tissue
nonthyroid,illness,syndrome,is,common,sepsis,acute,myocardial,infarction,trauma,is,associated,increased,mortality
,th,be,novel,treatment,setting,critical,illness,viral,infection,hypoxia,prevails
,present,study,aims,address,efficacy,safety,acute,administration,triiodothyronine,t3,critically,ill,covid19,infected,patients,requiring,mechanical,respiratory,support,extra,corporeal,membrane,oxygenation,ecmo
trial,design,study,is,phase,ii,parallel,2arm,11,ratio,multicentre,prospective,randomized,doubleblind,placebo,controlled,trial
participants,male,female,patients,aged,over,18,years,old,who,diagnosed,pulmonary,infection,covid19,admitted,intensive,care,unit,requiring,mechanical,ventilation,ecmo,will,be,enrolled,trial
patients,will,be,excluded,cases,pregnancy,severe,systemic,disease,life,expectancy,less,6,months,participation,trial,investigational,drug,device,corticosteroid,sympathomimetic,use,initiation,treatment
,data,will,be,collected,electronic,crf,files
participants,will,start,be,recruited,icu,center,attiko,university,hospital,greece
,aim,include,two,more,clinical,sites,trial,one,greece,one,germany,intervention,comparator,intervention,t3,solution,injection,10,mug
,dose,administered,will,be,08g,v
bolus,will,be,followed,infusion,0113g
after,first,48h,maintenance,dose,will,be,administered,corresponding,50,therapeutic,dose,0057g
drug,administration,will,stop,after,successful,weaning,end,follow,up,maximum,30,days
comparator,placebo,composition,dosage,identical,apart,active,substance
main,outcomes,primary,outcome,assessed,present,study,will,be,percentage,patients,successfully,weaned,after,30,days,followup
successful,weaning,is,defined,requirement,ventilatory,support,after,extubation,mechanical,support,support,ecmo,48,hours
randomisation,allocation,sequence,one,groups,will,be,prepared,sponsor,study
,11,treatment,allocation,will,be,adopted
,electronic,crf,will,be,used,incorporating,iwrs,order,assure,proper,randomization,unblinding,emergency,cases
,representative,sponsor,will,get,copy,randomization,codes
,information,randomization,codes,will,be,locked,database,until,time,interim,analysis,final,analysis,is,performed
blinding,masking,participants,caregivers,investigators,assessing,outcomes,will,be,blinded,group,assignment
numbers,be,randomised,sample,size,sample,size,60,patients,indicates,30,subjects,group,will,have,84,power,detect,estimated,difference,two,study,groups
,criterion,significance,alpha,has,been,set,005,test,is,2tailed
trial,status,protocol,number,t3inj02thysupport,version,03,11,2020
,trial,is,not,recruiting,yet
,trial,will,start,recruitment,june,18th,2020
estimated,recruitment,will,finish,june,18th,2021
trial,registration,triiodothyronine,treatment,critically,ill,patients,covid19,infection,thysupport,clinicaltrialsgov
identifier,nct04348513,date,trial,registration,april,16,2020,eudract,identifier,202000162313,date,trial,registration,april,22,2020,full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
cytoresc,cytosorb,rescue,critically,ill,patients,undergoing,covid19,cytokine,storm,structured,summary,study,protocol,randomized,controlled,trial
objectives,approximately,8,10,covid19,patients,present,serious,clinical,course,need,hospitalization,8,hospitalized,patients,need,icutreatment
currently,causal,therapy,is,available,treatment,is,purely,supportive
,main,reason,death,critically,ill,patients,is,acute,respiratory,failure
,number,patients,severe,hyperinflammatory,response,excessively,elevated,proinflammatory,cytokines,causes,vasoplegic,shock,resistant,vasopressor,therapy
,new,polystyrenebased,hemoadsorber,cytosorb,cytosorbents,inc,new,jersey,usa,has,been,shown,adsorb,effectively,cytokines,other,middle,molecular,weight,toxins,way,reducing,blood,concentrations
,has,been,routinely,used,clinical,practice,eu,other,conditions,where,cytokine,storm,occurs,observational,study,has,been,completed,covid19,patients
,hypothesized,extracorporeal,elimination,cytokines,critically,ill,covid19,patients,suspected,hyperinflammation,shock,stabilize,hemodynamics,improve,outcome
,primary,endpoint,is,time,until,resolution,vasoplegic,shock,is,well,implemented,clinically,relevant,endpoint,critical,care,studies
trial,design,phase,iib,multicenter,prospective,openlabel,randomized,11,parallel,group,pilot,study,comparing,additional,use,cytosorb,standard,care,cytosorb
participants,patients,recruited,intensive,care,units,icus,7,participating,centers,germany,approximately,10,icus
,patients,aged,18,80,positive,polymerase,chain,reaction,pcr,test,sarscov2,creactive,protein,crp,100,l,procalcitonin,pct,2,ngl,suspected,cytokine,storm,defined,via,vasoplegic,shock,norepinephrine,02,mugmin,achieve,mean,arterial,pressure,65mmhg
patients,included,irrespective,indication,renal,replacement,therapy
suspected,proven,bacterial,cause,vasoplegic,shock,is,contraindication
intervention,comparator,24,hours,after,meeting,inclusion,criteria,patients,will,be,randomized,receive,standard,care,standard,care,additional,cytosorb,therapy,via,shaldon,catheter,37,days
filter,exchange,is,every,24,hours
,patients,receive,antibiotics,additional,dose,antibiotics,is,administered,after,change,cytosorb,filter,order,prevent,underdosing,cytosorb,treatment
main,outcomes,primary,outcome,is,time,resolution,vasoplegic,shock,defined,need,vasopressors,least,8,hours,order,sustain,map,65mmhg,days
secondary,outcomes,7,day,mortality,after,fulfilling,inclusion,criteria,mortality,until,hospital,discharge,interleukin6,il6,measurement,day,1,3,need,mechanical,ventilation,duration,mechanical,ventilation,duration,icustay,catecholamine,dose,day,123,after,start,cytosorb,acute,kidney,injury
randomization,electronic,randomization,will,be,performed,study,software,secutrial,administered,clinical,study,center,csc,charite,universitatsmedizin,berlin,germany
randomization,is,blocks,4,stratified,including,center
blinding,masking,trial,will,be,nonblinded,clinicians,patients
,statistician,will,receive,blinded,data,set,analyses,will,be,conducted,blinded
numbers,be,randomized,sample,size,is,pilot,study,goal,examine,feasibility,study,design,well,intervention,effect,formal,sample,size,calculation,was,conducted
,total,number,approximately,80100,patients,is,planned,4050,patients,per,group
safety,assessment,is,after,inclusion,10,patients,per,randomization,group
trial,status,please,see,study,protocol,version,april,24,2020
recruitment,patients,is,still,pending
trial,registration,study,was,registered,april,27,2020,german,registry,clinical,trials,drks,under,number,drks00021447
full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
hypofractionated,radiotherapy,alone,24,gy,per,fraction,head,neck,cancer,covid19,pandemic,princess,margaret,experience,proposal
background,objective,study,was,identify,subgroup,patients,head,neck,squamous,cell,carcinoma,hnscc,who,be,suitable,hypofractionated,radiotherapy,rthypo,covid19,pandemic
methods,hnscc,cases,oropharynxlarynxhypopharynx,treated,definitive,rthypo,60,gy,25,fractions,over,5,weeks,moderately,accelerated,radiotherapy,rtacc,alone,70,gy,35,fractions,over,6,weeks,concurrent,chemoradiotherapy,ccrt,20052017,included
locoregional,control,lrc,distant,control,dc,after,rthypo,rtacc,ccrt,compared,subgroups
results,study,identified,994,human,papillomaviruspositive,hpv,oropharyngeal,squamous,cell,carcinoma,cases,61,254,679,receiving,rthypo,rtacc,ccrt,respectively,1045,hpv,hnscc,cases,263,451,331,receiving,rthypo,rtacc,ccrt,respectively
,ccrt,cohort,had,higher,tn,categories,whereas,radiotherapyalone,patients,older
rthypo,rtacc,ccrt,produced,comparable,3year,lrc,dc,hpv,t12n0n2a,disease,seventh,edition,tnm,system,tnm7,lrc,94,100,94,p,769
t1t2n2b,disease,lrc,90,94,97,p,445
,t12n2ct3n0n2c,disease,lrc,89,93,95,p,494
,lrc,was,similar,t4n3,disease,78,84,88,p,677
dc,was,lower,rthypo,rtacc,versus,ccrt,67,65,87,p,005
,hpv,hnscc,3year,lrc,dc,similar,rthypo,rtacc,ccrt,stages,ii,lrc,85,89,100,p,320
,rthypo,rtacc,had,lower,lrc,stage,iii,76,69,91,p,006
whereas,dc,rates,similar,92,85,90,p,410
lower,lrc,stage,iii,predominated,patients,laryngeal,squamous,cell,carcinoma,receiving,rtacc,62,not,rthypo,80,ccrt,92,rthypo,vs,ccrt,p,270
ccrt,had,numerically,higher,lrc,comparison,rthypo,rtacc,stage,iv,73,65,66,p,336
,is,proposed,rthypo,be,considered,place,ccrt,hpv,t1t3n0n2c,tnm7,hnsccs,hpv,t1t2n0,hnsccs,select,stage,iii,hnsccs,covid19,outbreak
agileaccord,randomized,multicentre,seamless,adaptive,phase,ii,platform,study,determine,optimal,dose,safety,efficacy,multiple,candidate,agents,treatment,covid19,structured,summary,study,protocol,randomised,platform,trial
objectives,phase,determine,optimal,dose,candidate,combination,candidates,entered,platform
phase,ii,determine,efficacy,safety,candidate,entered,platform,compared,current,standard,care,soc,recommend,whether,be,evaluated,later,phase,ii,iii,platforms
trial,design,agileaccord,is,bayesian,multicentre,multiarm,multidose,multistage,openlabel,adaptive,seamless,phase,ii,randomised,platform,trial,determine,optimal,dose,activity,safety,multiple,candidate,agents,treatment,covid19
designed,master,protocol,candidate,being,evaluated,own,subprotocol,candidate,specific,trial,cst,protocol,randomising,candidate,soc,21,allocation,favour,candidate,nb,first,candidate,has,gone,regulatory,approval,is,expected,open,recruitment,early,summer,2020
,dose,will,be,assessed,safety,sequentially,cohorts,6,patients
once,phase,ii,dose,has,been,identified,will,assess,efficacy,seamlessly,expanding,larger,cohort
participants,patient,populations,vary,csts,main,eligibility,criteria,include,adult,patients,18,years,who,have,laboratoryconfirmed,infection,severe,acute,respiratory,syndrome,coronavirus,2,sarscov2
,will,include,severe,mildmoderate,patients,defined,follows,group,severe,disease,patients,who,working,group,clinical,characteristics,covid19,infection,9point,ordinal,scale,grades,4,hospitalised,oxygen,mask,nasal,prongs,5,hospitalised,noninvasive,ventilation,high,flow,oxygen,6,hospitalised,intubation,mechanical,ventilation,7,hospitalised,ventilation,additional,organ,support,group,b,mildmoderate,disease,ambulant,hospitalised,patients,peripheral,capillary,oxygen,saturation,spo2,94,ra
,csts,included,community,setting,cst,protocol,will,clarify,whether,patients,suspected,sarscov2,infection,eligible
participants,will,be,recruited,england,north,ireland,wales,scotland
intervention,comparator,comparator,is,current,standard,care,soc,csts,plus,placebo
candidates,prevent,uncontrolled,cytokine,release,prevention,viral,replication,other,antiviral,treatment,strategies,stages,development,inclusion,agileaccord
other,csts,will,be,added,over,time
,is,not,set,limit,number,csts,include,agileaccord,master,protocol,will,upload,cst,publication,opens,recruitment
main,outcomes,phase,dose,limiting,toxicities,common,terminology,criteria,adverse,events,v5,grade,3,adverse,events
phase,ii,agreed,cst,basis,depending,mechanism,action,candidate,patient,population
,include,time,clinical,improvement,least,2,points,who,9point,category,ordinal,scale,measured,up,29,days,randomisation,progression,disease,oxygen,saturation,sao2,92,hospitalization,death,change,timeweighted,viral,load,measured,up,29,days,randomisation
randomisation,varies,cst,default,is,21,allocation,favour,candidate,maximise,early,safety,data
blinding,masking,safety,phase,openlabel,csts,include,placebo,soc,efficacy,phase
numbers,be,randomised,sample,size,varies,csts
,simulations,have,shown,around,16,participants,necessary,determine,futility,promise,candidate,given,dose,efficacy,evaluation,alone,32,40,participants,required,across,dosefinding,efficacy,evaluation,capping,maximum,number,participants,contributing,evaluation,treatment,40
trial,status,master,protocol,version,number,v5,07,2020,trial,is,setup,full,regulatory,approval,utilises,digital,technology,solutions,including,medidatas,rave,edc,electronic,data,capture,rtsm,randomisation,patient,econsent,ipads,via,rave,patient,cloud
,recruitment,dates,will,vary,csts,time,writing,csts,yet,open,recruitment
trial,registration,eudract,202000186027,14th,march,2020,full,protocol,full,protocol,is,attached,additional,file,accessible,trials,website,additional,file,1
,interest,expediting,dissemination,material,familiar,formatting,has,been,eliminated,letter,serves,summary,key,elements,full,protocol
effect,xuebijing,injection,inflammatory,markers,disease,outcome,coronavirus,disease,2019
objective,observe,influence,xuebijing,injection,inflammatory,markers,prognosis,coronavirus,disease,2019,covid19,patients
methods,sixty,severe,covid19,patients,admitted,changsha,public,health,treatment,center,north,hospital,first,hospital,changsha,city,january,march,2020,randomly,divided,routine,treatment,group,xuebijing,50,group,xuebijing,100,group,20,cases,group
,routine,treatment,group,was,treated,according,national,health,commissions,guide,covid19
,basis,conventional,treatment,xuebijing,injection,was,injected,50,twice,day,7,days,xuebijing,50,group,100,twice,day,7,days,xuebijing,100,group
,blood,routine,test,creactive,protein,crp,erythrocyte,sedimentation,rate,esr,acute,physiology,chronic,health,evaluation,ii,apache,ii,score,2019,novel,coronavirus,2019ncov,nucleic,acid,test,disease,classification,three,groups,8,days,after,treatment,observed
results,1,after,treatment,white,blood,cell,count,wbc,lymphocyte,count,lym,three,groups,increased,meanwhile,crp,esr,decreased
compared,routine,treatment,group,wbc,count,xuebijing,100,group,after,treatment,increased,x109l,712055
p,005,levels,crp,esr,xuebijing,50,100,groups,decreased,crp,l,32346
compared,xuebijing,50,group,increase,wbc,decrease,crp,esr,more,significant,xuebijing,100,group,wbc,x109l,712055
2,after,treatment,apache,ii,score,three,groups,decreased
,xuebijing,100,group,apache,ii,score,after,treatment,was,lower,routine,treatment,xuebijing,50,groups,12315,vs,16516
after,treatment,2019ncov,nucleic,acid,test,three,groups,partly,turned,negative,9,cases,routine,treatment,group,8,cases,xuebijing,50,group,9,cases,xuebijing,100,group,significant,difference,p,005
,conditions,patients,three,groups,improved,after,treatment,8,cases,routine,treatment,group,transformed,common,type,1,case,critical,type,9,cases,12,cases,xuebijing,50,group,100,group,transformed,common,type,respectively
xuebijing,100,group,was,improved,more,obviously,xuebijing,50,group,routine,treatment,group,p,005
,xuebijing,injection,effectively,improve,inflammatory,markers,prognosis,severe,covid19,patients
development,automatic,integrated,gene,detection,system,novel,severe,acute,respiratory,syndromerelated,coronavirus,sarscov,2
,december,2019,wuhan,china,suffered,serious,outbreak,novel,coronavirus,infectious,disease,covid,caused,novel,severe,acute,respiratory,syndromerelated,coronavirus,sarscov,2
,quickly,identify,pathogen,designed,screened,primer,sets,established,sensitive,specific,qrtpcr,assay,sarscov,2,lower,limit,detectionlod,was,148,95,ci,9821,copies,per,reaction
,combined,qrtpcr,assay,automatic,integration,system,nucleic,acid,extraction,amplification,thereby,establishing,automatic,integrated,gene,detection,system,aigs,sarscov,2,cross,reactive,analysis,performed,20,other,respiratory,viruses,37,nasopharyngeal,swabs,confirmed,100,specificity,assay
,two,fold,diluted,sarscov,2,culture,lod,aigs,was,confirmed,be,365copies95,ci,351375,was,comparable,conventional,q,rtpcr740copies,95,ci,689750
clinical,performances,aigs,assay,assessed,266,suspected,covid19,clinical,respiratory,tract,samples,tested,parallel,commercial,kit
,clinical,sensitivity,aigs,test,was,9762,95ci0932009951
based,commercial,kit,test,result,concordance,analysis,high,agreement,sarscov2,detection,two,assays,pearson,r,was,09623,95,ci0952309703,results,indicated,aigs,be,used,rapid,detection,sarscov,2,advantage,simple,operation,less,time,consuming,aigs,be,suitable,sarscov2,detection,primary,medical,institutions,great,help,improve,detection,efficiency,control,spread,covid19
